IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.212
AS - Asia 11.329
EU - Europa 10.151
SA - Sud America 2.374
AF - Africa 1.022
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 20
Totale 51.137
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.155
SG - Singapore 6.099
CN - Cina 3.485
IE - Irlanda 2.647
IT - Italia 2.587
UA - Ucraina 2.395
BR - Brasile 2.032
CA - Canada 906
RU - Federazione Russa 710
CI - Costa d'Avorio 679
VN - Vietnam 561
SE - Svezia 332
DE - Germania 313
GB - Regno Unito 303
IN - India 284
KR - Corea 220
SN - Senegal 139
AR - Argentina 135
FI - Finlandia 118
FR - Francia 112
NL - Olanda 107
PL - Polonia 101
MX - Messico 100
CH - Svizzera 88
JP - Giappone 83
BD - Bangladesh 82
UZ - Uzbekistan 82
ZA - Sudafrica 74
EC - Ecuador 65
AT - Austria 61
TR - Turchia 58
IQ - Iraq 54
ES - Italia 52
CZ - Repubblica Ceca 50
HK - Hong Kong 48
BE - Belgio 47
GR - Grecia 44
ID - Indonesia 37
LB - Libano 36
CO - Colombia 35
MA - Marocco 35
PK - Pakistan 27
VE - Venezuela 27
IR - Iran 26
AU - Australia 20
PY - Paraguay 20
CL - Cile 19
IL - Israele 19
BJ - Benin 18
EU - Europa 18
SA - Arabia Saudita 17
JO - Giordania 16
PE - Perù 16
EG - Egitto 15
KE - Kenya 15
AE - Emirati Arabi Uniti 14
TN - Tunisia 14
BG - Bulgaria 13
BO - Bolivia 13
LT - Lituania 13
DO - Repubblica Dominicana 12
NG - Nigeria 12
RS - Serbia 12
AZ - Azerbaigian 11
DZ - Algeria 10
KZ - Kazakistan 10
NO - Norvegia 9
RO - Romania 9
UY - Uruguay 9
CR - Costa Rica 7
MY - Malesia 7
NZ - Nuova Zelanda 7
PS - Palestinian Territory 7
JM - Giamaica 6
KW - Kuwait 6
NP - Nepal 6
OM - Oman 6
TH - Thailandia 6
AL - Albania 5
BH - Bahrain 5
PH - Filippine 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
BB - Barbados 4
PA - Panama 4
HN - Honduras 3
HU - Ungheria 3
LU - Lussemburgo 3
PT - Portogallo 3
AM - Armenia 2
AO - Angola 2
BF - Burkina Faso 2
DK - Danimarca 2
EE - Estonia 2
GD - Grenada 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NI - Nicaragua 2
SR - Suriname 2
SV - El Salvador 2
Totale 51.110
Salva come PNG Salva come JPEG
Città #
Dallas 5.116
Santa Clara 2.900
Singapore 2.725
Jacksonville 2.636
Dublin 2.628
Chandler 2.134
Boardman 1.117
Chicago 955
Catania 899
Ashburn 836
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Abidjan 677
Toronto 650
Houston 510
Hefei 501
Des Moines 423
Beijing 394
San Mateo 386
Los Angeles 379
Nanchang 262
Wilmington 261
Civitanova Marche 229
Seoul 220
Saint Petersburg 182
Shenyang 180
Hebei 176
São Paulo 175
Ho Chi Minh City 173
Ottawa 148
Jiaxing 147
Dakar 138
New York 137
Changsha 134
Florence 133
Buffalo 132
Tianjin 110
Hanoi 105
Rome 100
Grafing 96
Council Bluffs 94
Kochi 92
Dong Ket 87
Milan 85
Palermo 74
Munich 71
Tokyo 71
Brooklyn 70
Seattle 66
Moscow 65
Warsaw 63
Rio de Janeiro 58
Washington 58
Montreal 57
Stockholm 52
Boston 51
The Dalles 51
Johannesburg 50
San Francisco 49
Belo Horizonte 47
Columbus 46
Hangzhou 45
Hong Kong 45
Phoenix 44
Redondo Beach 44
Brussels 42
Turku 42
Chennai 40
Den Haag 39
Poplar 39
Helsinki 38
Denver 37
Lappeenranta 37
Norwalk 37
Kunming 35
Atlanta 32
Falls Church 32
Mexico City 32
Pune 32
Tashkent 32
Mumbai 31
London 30
Jinan 29
Porto Alegre 29
Bremen 28
Orem 28
Amsterdam 27
Brasília 27
Curitiba 26
Ankara 25
Guangzhou 25
Campinas 24
Bari 22
Brno 22
Guayaquil 22
Messina 22
Quito 22
Ann Arbor 20
Totale 34.546
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 247
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 247
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 186
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 179
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 179
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 172
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 159
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 156
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 153
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 149
Il Rasario. Semeiotica medica 145
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 139
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 139
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 135
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 134
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 132
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 131
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 130
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 130
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 129
Hedgehog signaling pathways in multiple myeloma 125
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 124
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 123
A snapshot of asparaginase-induced liver insufficiency. 123
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 123
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 122
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 121
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 121
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 120
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 119
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 119
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 119
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 118
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 118
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 117
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 117
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 116
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 116
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 115
Acute pre-hepatic portal thrombosis: diagnosis and therapy 114
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 114
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 114
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 113
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 113
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 112
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 112
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 112
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 112
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 111
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 111
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 110
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 110
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 109
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 109
A case of high-risk AML in a patient with advanced systemic mastocytosis 108
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 108
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 108
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 108
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 108
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 107
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 107
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 106
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 106
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 105
Terapia del mieloma multiplo 105
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 105
A GLOBAL PROGRESSION RISK SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: THE NEVER-ENDING STORY 105
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 105
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 105
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 104
Bone turnover markers in patients with type 1 Gaucher disease 104
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 103
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 103
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 102
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 102
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 102
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 102
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 102
Eventi avversi e trigger C12: Stroke in ospedale 102
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 101
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 101
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 100
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 100
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 98
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 97
Acute myeloid leukemia in elderly patients. 97
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 97
A Multicentric clinical trial of salvage therapy with thalidomide for patients with advanced relapsed and refractory multiple myeloma 96
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 96
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 96
BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia 95
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 95
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 95
Multiple Myeloma in 2023 Ways: From Trials to Real Life 94
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 94
Angiogenesis in acute myeloid leukemia 94
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 94
The Heme Oxygenase System in Hematological Malignancies 94
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 94
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 94
Totale 11.767
Salva come PNG Salva come JPEG
Categoria #
all - tutte 197.440
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 197.440
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.881 0 0 0 0 1.175 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/202613.277 1.673 1.754 5.013 1.882 2.955 0 0 0 0 0 0 0
Totale 52.193